Innovation for women’s health

We are one of the few healthcare companies dedicated to advancing scientific innovations that support women’s health.

Our focus areas

We focus our efforts on areas where critical therapeutic gaps exist in women’s health. We take a broad view of women’s health and focus our R&D efforts on pursuing opportunities that address conditions that are unique to women, affect them disproportionately or impact them differently. They include but are not limited to:

  • Maternal and peripartum conditions (postpartum hemorrhage)
  • Infertility
  • Unintended pregnancy (contraception)
  • Conditions unique to women (bacterial vaginosis, polycystic ovarian syndrome, menopause)
  • Conditions affecting women disproportiontely (migraine, urinary incontinence, autoimmune diseases)
  • Conditions affecting women differently (mental health, cardiovascular disease, cancer) 
diverse women standing in 3 rows shoulder to shoulder

We are actively pursuing opportunities to invest in medical products, including drugs, devices, diagnostics and digital solutions that have the potential to address the complete health of women, particularly where therapeutic gaps exist.

  • By taking a broad view of women’s health, we are pursuing innovations to address the health of the whole woman across her life span.
  • Many conditions affect women at every stage of life, and there remain many areas of high and unmet needs in therapeutic options for treating these conditions. 

Women play a critical role* in maintaining their family’s health, and by prioritizing their own health, they can positively impact the health of their family. ​When we invest in women’s health, we’re investing in individual women, their families and their communities as well as their country’s economy and future.    

  • Women will spend an average of nine years** in poor health (25% more than men).
  • On average, women are diagnosed significantly later than men across more than 700 diseases*** — including cancer.  

For more information on our strategy, goals and progress, please see our ESG highlights document in the ESG reporting center. 

Research and development  

Image of female scientist representing research and development

Since our launch in 2021, Organon has been building an R&D portfolio that includes a variety of innovative assets across women’s health, including of clinical-stage trials and commercialized medicines and devices.

Our research interests in 2024 included:  

  • A biosimilars commercialization agreement or collaboration to treat breast cancer and osteoporosis
  • Postpartum hemorrhage, a major contributor to maternal morbidity
  • Endometriosis-related pain, a common and chronic condition affecting up to one in 10 women of reproductive age globally****
  • Hormone-free, on-demand contraception, an option preferred by many women who have few effective alternatives
  • An option to acquire a device for use during minimally invasive laparoscopic hysterectomy

Collaboration and partnerships for innovation  

We know that healthy women are the bedrock of a thriving, stable and resilient society.

By convening and catalyzing an ecosystem of like-minded partners and innovators, we can spark collective action to deliver a new era in healthcare — improving research, enhancing education, investing in partnerships to expand options and advancing gender equity. Our goal is to nurture this ecosystem to advance the field and improve women’s lives 

By engaging in partnerships with innovators across the healthcare ecosystem, including companies, academic institutions, foundations, NGOs, venture capital and healthcare providers, we aim to identify emerging science and accelerate access to new medicines, devices and solutions for women and girls around the world.

Learn more about our work in business development.

Fostering innovation throughout the R&D pipeline  

Organon is dedicated to pursuing scientific innovations for women’s health, prioritizing areas where critical therapeutic gaps exist. Our goal is to build an industry-leading pipeline of therapeutics and devices to address women’s unmet needs — with both early- and late-stage assets. Through a focused and active external innovation strategy, Organon is constantly exploring emerging science with the opportunity to provide better healthcare solutions for women.

Pregnant woman and man at computer

Learn more about our work on product quality and safety and access to medicines and healthcare.


*The Health of Women and Girls Determines the Health and Well-Being of Our Modern World: A White Paper From the International Council on Women’s Health Issues – PMC, National Library of Medicine

**Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies, McKinsey Health Institute

***Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies, McKinsey Health Institute

****This research interest was pursued in 2024 but has since been discontinued.